In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mitsubishi Tanabe Pharma Corp.

Division of Mitsubishi Chemical Holdings Corp.
www.mt-pharma.co.jp/e/

Latest From Mitsubishi Tanabe Pharma Corp.

Hello NMPA: New Drug Approvals, Online Database And More

China grants approvals to Gilead’s HIV combo Biktarvy and Mitsubishi Tanabe Pharma’s Radicava in the latest batch of new product clearances. Meanwhile, a new online database for marketing authorization holders goes live.

Approvals China

Kolon Ends One Asian Invossa Contract, But Hopes To Keep Others

Korean firm Kolon terminates one Asia supply contract for Invossa, but appears hopeful it can maintain other remaining deals as it counts on resuming US clinical trials with the troubled gene therapy.

South Korea Gene Therapy

Vadadustat Emerges As Japan HIF-PHI Leader With First Filing Globally

Competition intensifies in novel anemia therapy space in Japan with first filing globally for Akebia/Mitsubishi Tanabe’s contender vadadustat, which could see its first launch worldwide in the country.

Japan Commercial

Positive Results Move Anemia Contender Enarodustat Towards First Filing

Japanese firms unveil pivotal top-line results that pave way for first filing of novel anemia therapy within new class of agents, but competition is high and timings remain unclear.

Japan Clinical Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register